#1 Clinical Trials Search in Europe

Gefitinib

Gefitinib, also known as Iressa or ZD1839, is a targeted therapy drug being studied in clinical trials for various types of cancer. This article summarizes key information about Gefitinib’s use in clinical trials, including its potential benefits, side effects, and effectiveness in treating different cancers such as lung cancer, head and neck cancer, and leukemia.

Table of Contents

What is Gefitinib?

Gefitinib, also known by its brand names Iressa or ZD1839, is a medication used in cancer treatment[1][2]. It belongs to a class of drugs called epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. These drugs work by targeting specific proteins on cancer cells to slow down or stop their growth[3].

How Gefitinib Works

Gefitinib works by blocking a protein called epidermal growth factor receptor (EGFR) on the surface of cancer cells. When EGFR is stimulated, it triggers a series of chemical reactions that tell the tumor to grow. By blocking EGFR, Gefitinib aims to stop these reactions and prevent the tumor from growing or spreading[3].

Conditions Treated with Gefitinib

Gefitinib has been studied and used in the treatment of various types of cancer, including:

  • Non-small cell lung cancer (NSCLC): Gefitinib is approved by the FDA for treating advanced lung cancer, particularly in patients with specific genetic mutations in their EGFR gene[2][3].
  • Head and neck cancer: Research is ongoing to evaluate Gefitinib’s effectiveness in treating advanced head and neck cancers[4][5].
  • Skin cancer: Studies have investigated the use of Gefitinib in treating recurrent or metastatic squamous cell carcinoma of the skin[3].
  • Acute myelogenous leukemia: Research has explored the potential of Gefitinib in treating this type of blood cancer[6].
  • Pancreatic cancer: Clinical trials have examined the combination of Gefitinib with other treatments for metastatic pancreatic cancer[7].
  • Hepatocellular carcinoma (liver cancer): Studies have investigated Gefitinib as an adjuvant therapy (additional treatment after surgery) for patients with resectable liver cancer[8].
  • Esophageal and gastroesophageal junction cancer: Research has explored the effectiveness of Gefitinib in treating recurrent or metastatic cancers in these areas[9].

How Gefitinib is Administered

Gefitinib is typically taken as an oral medication in the form of tablets. The dosage and duration of treatment can vary depending on the specific condition being treated and the individual patient’s needs. Some common administration methods include:

  • Daily dosing of 250 mg tablets[2][5].
  • Higher doses of 500 mg or 750 mg daily in some studies[4][6].
  • Continuous daily dosing without interruption[7].

It’s important to note that Gefitinib should only be taken as prescribed by a healthcare professional, and patients should follow their doctor’s instructions carefully.

Potential Side Effects

Like all medications, Gefitinib can cause side effects. While not everyone experiences side effects, it’s important to be aware of potential issues. Common side effects may include:

  • Skin rash or acne-like eruptions
  • Diarrhea
  • Nausea
  • Loss of appetite
  • Fatigue

More serious side effects, though less common, can include lung problems (such as interstitial lung disease) and liver problems. Patients should report any unusual symptoms or side effects to their healthcare provider promptly[1][2].

Ongoing Research and Clinical Trials

Researchers continue to study Gefitinib to better understand its effectiveness and potential applications in cancer treatment. Some areas of ongoing research include:

  • Combining Gefitinib with other cancer treatments, such as chemotherapy or radiation therapy, to enhance its effectiveness[4][5].
  • Using Gefitinib as an adjuvant therapy after surgery to prevent cancer recurrence[8].
  • Exploring the use of Gefitinib in different types of cancer and at various stages of disease progression[9].
  • Investigating biomarkers that may help predict which patients are most likely to benefit from Gefitinib treatment[8].

These ongoing studies aim to improve our understanding of Gefitinib and optimize its use in cancer treatment, potentially expanding its applications and benefits for patients in the future.

Aspect Details
Drug Name Gefitinib (Iressa, ZD1839)
Mechanism of Action Blocks epidermal growth factor receptor (EGFR) to inhibit cancer cell growth
Administration Oral tablet, typically once daily
Cancer Types Studied Non-small cell lung cancer, head and neck cancer, acute myelogenous leukemia, pancreatic cancer, hepatocellular carcinoma, esophageal cancer, mesothelioma
Clinical Trial Phases Primarily Phase II studies
Primary Outcomes Response rate, progression-free survival, overall survival
Combination Therapies Studied with chemotherapy, radiotherapy, and other targeted therapies
Patient Populations Includes both previously treated and untreated patients, various cancer stages
Ongoing Research Efficacy in different cancer types, optimal dosing, combination strategies

FAQ

  • What is Gefitinib (Iressa)? Gefitinib, also known as Iressa or ZD1839, is a targeted therapy drug that works by blocking the epidermal growth factor receptor (EGFR), which is involved in cancer cell growth. It is being studied in clinical trials for various types of cancer.
  • What types of cancer is Gefitinib being studied for? Gefitinib is being studied in clinical trials for several types of cancer, including non-small cell lung cancer, head and neck cancer, acute myelogenous leukemia, pancreatic cancer, hepatocellular carcinoma (liver cancer), esophageal cancer, and mesothelioma.
  • How is Gefitinib administered? Gefitinib is typically administered orally as a tablet, usually once daily. The dosage may vary depending on the specific clinical trial and cancer type being studied.
  • What are some potential side effects of Gefitinib? While specific side effects are not detailed in the provided information, targeted therapies like Gefitinib generally have fewer side effects compared to traditional chemotherapy. However, patients should discuss potential side effects with their healthcare provider.
  • How effective is Gefitinib in treating cancer? The effectiveness of Gefitinib varies depending on the type of cancer and individual patient factors. Clinical trials are ongoing to determine its efficacy in different cancer types. Some trials have shown promising results in terms of tumor response and disease control.

Ongoing Clinical Trials on Gefitinib

  • Study on the Effectiveness and Safety of Lazertinib and Gefitinib for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece Hungary

  • Study for Patients with cMET-Dependent Cancers to Continue Treatment with Capmatinib, Nazartinib, and Gefitinib

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium Germany Italy

Glossary

  • Gefitinib: A targeted therapy drug that blocks the epidermal growth factor receptor (EGFR), potentially slowing or stopping cancer cell growth.
  • Iressa: The brand name for Gefitinib, also known as ZD1839.
  • Epidermal Growth Factor Receptor (EGFR): A protein on the surface of cells that, when stimulated, can lead to cancer cell growth. Gefitinib targets and blocks this receptor.
  • Targeted Therapy: A type of cancer treatment that targets specific genes or proteins involved in cancer growth and survival.
  • Clinical Trial: A research study that tests how well new medical approaches work in people, such as new ways to prevent, detect, diagnose, or treat diseases like cancer.
  • Response Rate: The percentage of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival: The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival: The length of time from the start of treatment that patients are still alive.
  • Adjuvant Therapy: Additional cancer treatment given after the primary treatment to lower the risk of cancer recurrence.
  • Metastatic Cancer: Cancer that has spread from its original site to other parts of the body.

References

  1. https://clinicaltrials.gov/study/NCT00188617
  2. https://clinicaltrials.gov/study/NCT01774721
  3. https://clinicaltrials.gov/study/NCT00054691
  4. https://clinicaltrials.gov/study/NCT01185171
  5. https://clinicaltrials.gov/study/NCT00681967
  6. https://clinicaltrials.gov/study/NCT00130702
  7. https://clinicaltrials.gov/study/NCT00137761
  8. https://clinicaltrials.gov/study/NCT00282100
  9. https://clinicaltrials.gov/study/NCT00268346